#Singapore #Australia #Incyte #Specialised Therapeutics #Ruxolitinib

Expansion of Partnership with Incyte for Ruxolitinib Cream in Australia

Specialised Therapeutics (ST), a leading independent biopharmaceutical company, has recently announced an exciting extension of its existing collaboration with Incyte Biosciences International. This partnership now includes the commercialization of ruxolitinib cream, better known as Opzelura, in Australia. This development is significant as ruxolitinib cream represents a breakthrough in treating several chronic skin conditions that can heavily impact patients' lives.

Ruxolitinib cream is a topical Janus kinase (JAK) inhibitor, which is designed to treat various dermatological issues. In the United States, it is approved for the treatment of non-segmental vitiligo in individuals aged 12 years and older. Additionally, it is also indicated for short-term treatment of mild to moderate atopic dermatitis in patients aged two and older, specifically for those whose conditions are not adequately controlled by traditional topical therapies.

Under this renewed agreement, Incyte remains in charge of the development and manufacturing aspects of ruxolitinib cream. At the same time, Specialised Therapeutics will take the lead in managing regulatory submissions, medical affairs, marketing, and distribution for the Australian market.

Mr. Carlo Montagner, the CEO of Specialised Therapeutics, expressed his enthusiasm regarding this strategic expansion. He emphasized the importance of bringing ruxolitinib cream to patients in Australia, as atopic dermatitis and vitiligo can significantly affect both physical health and psychological wellness. "Our collaboration with Incyte commenced in 2021, and extending our partnership into dermatology underscores our commitment to providing innovative therapeutic options in areas where patient needs are still not fully met," he remarked.

The primary focus now lies in ensuring a seamless navigation through local regulatory and reimbursement procedures. This is crucial to guarantee that eligible patients in Australia can access this vital treatment promptly and fairly.

Lee Heeson, Head of International at Incyte, reiterated the value of their partnership with Specialised Therapeutics. He stated, “We are pleased to broaden our partnership with Specialised Therapeutics as we strive to make ruxolitinib cream available to eligible patients in Australia. ST has demonstrated proven expertise in navigating the regulatory and commercial pathways throughout this region, making them a vital collaborator for our mission to enhance access to our therapies globally.”

This expansion signifies a notable progression in ST’s portfolio into the realm of inflammatory dermatology, showcasing their commitment to innovation and excellence in patient care. The company anticipates moving forward with the regulatory and reimbursement processes involving the Australian healthcare authorities for Opzelura shortly.

About Specialised Therapeutics

Founded in 2007, Specialised Therapeutics operates as an independent specialty pharmaceutical firm, dedicated to providing innovative therapies across Australia, New Zealand, and Southeast Asia. With its headquarters in Singapore, ST collaborates with global pharmaceutical companies to deliver novel healthcare solutions, particularly in therapeutic areas such as oncology, dermatology, and more. Their mission is simple yet powerful: to offer specialized therapies where there are unmet medical needs, ensuring communities gain access to crucial healthcare advancements.

Understanding Ruxolitinib Cream (Opzelura)

Ruxolitinib cream (Opzelura) is recognized as the first treatment approved by the FDA, aimed explicitly at repigmentation for non-segmental vitiligo, making it a groundbreaking option for patients. This treatment not only emphasizes the advancement in dermatological pharmaceuticals but also enlightens the pathway towards addressing the psychological and physical challenges faced by those suffering from chronic skin conditions.

With over one million patients treated globally, the impact of OPZELURA continues to grow, paving the way for future innovations in the dermatological space. As Specialised Therapeutics embarks on this pivotal journey with Incyte, the future looks promising for those affected by these chronic skin disorders in Australia.